No Data
Zhejiang Zhenyuan Share (000705.SZ) plans to sign the "Capital Increase Agreement" with CHINARES PHARMA.
On December 24th, Gelonghui reported that Zhejiang Zhenyuan Share (000705.SZ) announced that it has carried out a capital increase by introducing strategic investors for its wholly-owned subsidiary, Shaoxing Zhenyuan Pharmaceutical Operation Co., Ltd. (referred to as "Zhenyuan Pharmaceuticals"), through a public listing at the Shaoxing Property Exchange. After review by the exchange and confirmation by the company, CHINARES PHARMA was determined to be the qualified investor for the capital increase, and a "Capital Increase Agreement" is planned to be signed with CHINARES PHARMA at a price of 1.439517 yuan per registered capital, with an increase amount of 119.8618235 million yuan.
CHINARES PHARMA (03320.HK): Completed the proposed internal restructuring involving China Resources Shengkai.
On December 20, Gelonghui reported that CHINARES PHARMA (03320.HK) announced a proposed internal restructuring involving its non-wholly owned subsidiary, Kunming CHINARES Shenghuo Pharmaceutical Co., Ltd. ("CHINARES Shenghuo"). On December 20, 2024, according to the terms of the Equity Transfer Agreement, China Resources Sanjiu Medical & Pharmaceutical proposed to transfer 51% equity in CHINARES Shenghuo to Kunming Pharmaceutical. The trade has completed business registration, and the transfer has been finalized.
The current cycle of Traditional Chinese Medicine materials is entering a downturn phase, and pharmaceutical companies may face a cost "turning point."
In the second half of 2024, the prices of Traditional Chinese Medicine materials are expected to decline overall; the semi-annual and third quarter reports of this year show that the gross margin of some Chinese Patent Medicine listed companies has significantly decreased, indicating a notable impact of the fluctuation in Traditional Chinese Medicine material prices on costs. However, with the retreat in Traditional Chinese Medicine material prices, production costs for companies will also decrease.
Announcement Highlights | In the first 11 months, SUNSHINE INS's original premium income exceeded 120 billion yuan; GCL TECH plans to allot up to 1.56 billion shares, net raising approximately 1.53 billion Hong Kong dollars.
In the first 11 months, SUNSHINE INS's original premium income exceeded 120 billion yuan; the major Shareholder of CHENGDU EXPWAY won a highway project worth over 10 billion yuan.
CHINARES PHARMA's subsidiary CHINARES PHARMA Holdings has increased its Shareholding in China Resources Boya Bio-pharmaceutical Group to 1%.
CHINARES PHARMA (03320) announced that from November 8, 2024, to December 18, 2024, the company's wholly-owned subsidiary, CHINARES PHARMA Holdings, has cumulatively acquired an additional 5.0424 million shares of China Resources Boya Bio-pharmaceutical Group through the centralized competitive trading system of the Shenzhen Stock Exchange, accounting for 1.00% of the total share capital of China Resources Boya Bio-pharmaceutical Group. As of the date of this announcement and after the aforementioned shareholding increase, the company indirectly holds approximately 30.28% of the total share capital and approximately 41.59% of the voting rights of China Resources Boya Bio-pharmaceutical Group through CHINARES PHARMA Holdings. China Resources Boya Bio-pharmaceutical Group is accounted for as a subsidiary of the company.
We Think China Resources Pharmaceutical Group (HKG:3320) Can Stay On Top Of Its Debt
No Data
